MusthInsider

Latest On Corvus Pharmaceuticals, Inc (CRVS):

Updated on: March 19, 2021

Date/Time	Type	Description	Signal
2023-05-12 22:21 EST	News	Corvus Pharmaceuticals: Targeting $1 Billion/Year U.S. T-Cell Lymphoma Market	N/A
2023-05-08 22:39 EST	News	Corvus Pharmaceuticals GAAP EPS of -$0.17 misses by $0.01	N/A
2023-05-08 22:39 EST	News	Corvus Pharmaceuticals, Inc. (CRVS) Q1 2023 Earnings Call Transcript	N/A
2023-05-07 20:51 EST	News	Corvus Pharmaceuticals Q1 2023 Earnings Preview	N/A
2023-03-29 11:09 EST	News	Corvus Pharmaceuticals, Inc. (CRVS) Q4 2022 Earnings Call Transcript	N/A
2023-03-28 20:35 EST	News	Corvus Pharmaceuticals GAAP EPS of -$0.21 beats by $0.02	N/A
2022-11-07 01:12 EST	News	Corvus Pharmaceuticals, Inc. (CRVS) Q3 2022 Earnings Call Transcript	N/A
2022-11-04 01:21 EST	News	Corvus Pharmaceuticals GAAP EPS of -$0.32 misses by $0.16	N/A
2022-11-03 07:35 EST	News	Corvus Pharmaceuticals Q3 2022 Earnings Preview	N/A
2022-09-26 18:13 EST	News	Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China	N/A
2022-08-09 00:57 EST	News	Corvus Pharmaceuticals GAAP EPS of -$0.18 in-line	N/A
2022-08-09 00:56 EST	News	Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2022 Results - Earnings Call Transcript	N/A
2022-08-06 08:07 EST	News	Corvus Pharmaceuticals Q2 2022 Earnings Preview	N/A
2022-05-06 01:39 EST	News	Corvus Pharmaceuticals GAAP EPS of -$0.18	N/A
2022-03-11 09:34 EST	News	Corvus Pharmaceuticals GAAP EPS of -$0.20 misses by $0.01	N/A
2022-03-11 09:34 EST	News	Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2021 Results - Earnings Call Transcript	N/A
2022-03-09 22:06 EST	News	Corvus Pharmaceuticals Q4 2021 Earnings Preview	N/A
2022-01-14 06:28 EST	News	Corvus Pharma initiates Phase 1/1b trial of CPI-818 for T-cell lymphomas in China	N/A
2021-12-11 08:34 EST	News	Checking In On Corvus Pharmaceuticals	N/A
2021-11-01 17:42 EST	News	Corvus Pharmaceuticals EPS misses by $0.03	N/A
2021-09-24 02:10 EST	News	Corvus Pharmaceuticals: More Than A CD73 Sympathy Play	N/A
2021-09-23 00:42 EST	News	Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming	N/A
2021-09-21 15:24 EST	News	AstraZeneca lung cancer data propel Corvus and Arcus	N/A
2021-09-21 15:23 EST	News	CRVS, APRE, GDS and OYST among after hours movers	N/A
2021-09-21 15:23 EST	News	Corvus Pharma has stellar day closing 135% higher; reaches 52-week high after-hours	N/A
2021-09-21 15:20 EST	News	APRE, GMAB, VRCA and CRVS among after hours movers	N/A
2021-09-21 15:18 EST	News	Corvus Pharma extends gains to more than double in value this year	N/A
2021-08-17 11:34 EST	News	Corvus Pharma to commence Phase 1/1b trial of CPI-818 in China	N/A
2021-08-03 09:45 EST	News	Corvus Pharmaceuticals EPS in-line	N/A
2021-07-21 03:20 EST	News	Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target	N/A
2021-07-21 02:29 EST	News	Corvus shares drop after scrapping late-stage mupadolimab COVID-19 trial	N/A
2021-07-21 02:28 EST	News	Corvus Pharma praised for its focus after end to COVID-19 study	N/A
2021-03-25 12:00 EST	News	Corvus Pharmaceuticals EPS beats by $1.16	N/A
2021-03-12 22:57 EST	News	Corvus Pharmaceuticals (CRVS) Investor Presentation - Slideshow	N/A
2021-02-23 03:28 EST	Analyst Rating	The Analyst Target Price has increased from $8.6 to $9.25.	Buy
2021-02-20 01:27 EST	News	Corvus Pharma surges after an insider purchase of ~1.3M shares	N/A
2021-02-17 19:28 EST	News	Corvus closes 8.6M share public offering	N/A
2021-02-12 16:58 EST	News	Corvus shares slide after pricing 8.57M public offering	N/A
2021-02-11 23:25 EST	News	Corvus Pharma announces proposed public offering	N/A
2021-02-11 11:23 EST	Analyst Rating	The Analyst Target Price has decreased from $9.2 to $8.6.	Neutral
2021-02-11 05:12 EST	News	Corvus cut to neutral at Mizuho citing realignment of pipeline	N/A
2021-01-20 16:29 EST	News	Corvus Pharmaceuticals: Undervalued Based On COVID-19 Opportunity And Oncology Assets	N/A
2020-12-13 03:43 EST	Financials	Company financials have been released.	Neutral
2020-11-10 10:46 EST	News	Corvus' immunotherapy shows durable benefit in COVID-19	N/A
2020-11-07 15:30 EST	Financials	Company financials have been released.	Neutral
2020-11-07 06:14 EST	News	Seeking Alpha Catalyst Watch	N/A
2020-11-02 17:03 EST	Analyst Rating	The Analyst Target Price has decreased from $9.6 to $9.2.	Neutral
2020-11-01 23:28 EST	Financials	Company financials have been released.	Neutral
2020-10-30 20:36 EST	Earnings Estimate	An EPS average of -$0.33 is estimated for the quarter ending on March 31, 2021.	N/A
2020-10-07 16:40 EST	Analyst Rating	The Analyst Target Price has increased from $9.2 to $9.6.	Buy

About Corvus Pharmaceuticals, Inc (CRVS):

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial. Corvus Pharmaceuticals, Inc. also entered into a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was founded in 2014 and is based in Burlingame, California.

See Advanced Chart

General

Name Corvus Pharmaceuticals, Inc
Symbol CRVS
Type Common Stock
Exchange NASDAQ
Currency USD
Country USA
SectorHealthcare
IndustryBiotechnology
Full Time Employees 52
Fiscal Year EndDecember
IPO Date2016-03-23
Gic SectorHealth Care
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryBiotechnology
Gic SubIndustryBiotechnology
Web URLhttp://www.corvuspharma.com

Valuation

Price/Book (Most Recent Quarter) 2.95
Enterprise Value EBITDA 0.14

Financials

Most Recent Quarter 2020-09-30
Next Quarter EPS Estimate -$0.23
Return on Assets -38%
Return on Equity -72%
Earnings Per Share -$1.56
Revenue Per Share $0
Quarterly Earnings Growth 0%

Highlights

Market Capitalization 120.35 million
EBITDA -47441000
Analyst Target Price $9.25
Book Value Per Share $1.51

Share Statistics

Shares Outstanding 37.85 million
Shares Float 17.12 million
% Held by Insiders 498%
% Held by Institutions 63.75%
Shares Short 1.27 million
Shares Short Prior Month 1.24 million
Short Ratio 0.76
Short % of Float 5%
Short % of Shares Outstanding 3%

Technicals

Beta 1.77
52 Week High $5.28
52 Week Low $1.91
50 Day Moving Average 3.63
200 Day Moving Average 3.89

Dividends

Dividend Date N/A
ExDividend Date N/A
Dividend Yield 0%

Corvus Pharmaceuticals, Inc (CRVS) Dividend Calendar:

Ex-Dividend Date	Payment Date	Record Date	Declared Date	Amount

Corvus Pharmaceuticals, Inc (CRVS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.

Quarter Date	Report Date	Actual Revenue	Reported EPS	EPS Estimate	Deviation from Estimate
2020-09-30	2020-10-29	$N/A	-$0.33	-$0.22	-51.72%
2020-06-30	2020-07-30	$N/A	-$0.36	-$0.24	-51.58%
2020-03-31	2020-04-30	$N/A	-$0.44	-$0.41	-8.64%
2019-12-31	2020-03-05	$N/A	-$0.38	-$0.31	-22.58%
2019-09-30	2019-10-29	$N/A	-$0.37	-$0.43	13.29%
2019-06-30	2019-08-01	$N/A	-$0.44	-$0.44	-0.76%
2019-03-31	2019-05-09	$N/A	-$0.40	-$0.48	16.05%
2018-12-31	2019-03-07	$N/A	-$0.36	-$0.50	28%
2018-09-30	2018-11-01	$N/A	-$0.36	-$0.49	26.03%
2018-06-30	2018-08-02	$N/A	-$0.40	-$0.61	34.16%
2018-03-31	2018-05-03	$N/A	-$0.63	-$0.77	18%
2017-12-31	2018-03-01	$N/A	-$0.58	-$0.77	24.58%
2017-09-30	2017-11-02	$N/A	-$0.62	-$0.84	25.82%
2017-06-30	2017-08-03	$N/A	-$0.73	-$0.74	1.12%
2017-03-31	2017-05-04	$N/A	-$0.79	-$0.77	-2.6%
2016-12-31	2017-03-10	$N/A	-$0.55	-$0.55	-0.73%
2016-09-30	2016-11-03	$N/A	-$0.51	-$0.45	-13.33%
2016-06-30	2016-08-04	$N/A	-$0.43	-$0.32	-36.38%
2016-03-31	2016-05-05	$N/A	-$5.39	-$6.09	11.49%

Corvus Pharmaceuticals, Inc (CRVS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:

Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares

Cash Flow:

Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures

Balance Sheet:

Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Corvus Pharmaceuticals, Inc (CRVS) Chart:

Corvus Pharmaceuticals, Inc (CRVS) News:

Below you will find a list of latest news for Corvus Pharmaceuticals, Inc (CRVS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Corvus Pharmaceuticals, Inc (CRVS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date:

Options Type:

Moneyness:

Expiration Date	Strike	Last Price	Type	Volume	Open Interest	Implied Volatility	In The Money	Change	Change Percent
2025-05-16	1	0	CALL	0	0	1444.09	TRUE	0	0
2025-05-16	2	2.1	CALL	9	90	464.52	TRUE	-0.2	-0.09
2025-05-16	3	1.2	CALL	3	54	347.82	TRUE	-0.23	-0.16
2025-05-16	4	0.2	CALL	187	1569	101.17	TRUE	-0.35	-0.64
2025-05-16	5	0.05	CALL	68	3738	172.91	FALSE	-0.09	-0.64
2025-05-16	6	0.03	CALL	1	1489	237.27	FALSE	-0.02	-0.4
2025-05-16	7	0.03	CALL	501	540	304.61	FALSE	-0.02	-0.4
2025-05-16	8	0.05	CALL	0	260	397.02	FALSE	0	0
2025-05-16	9	0.35	CALL	0	13	546.38	FALSE	0	0
2025-05-16	10	0.15	CALL	0	204	433.9	FALSE	0	0
2025-05-16	1	0.04	PUT	0	51	767.11	FALSE	0	0
2025-05-16	2	0.03	PUT	0	1984	410.21	FALSE	0	0
2025-05-16	3	0.04	PUT	53	2706	226.97	FALSE	0	0
2025-05-16	4	0.15	PUT	89	624	105.25	FALSE	0	0
2025-05-16	5	1	PUT	4	28	179.92	TRUE	0.15	0.18
2025-05-16	6	2.8	PUT	0	45	515.91	TRUE	0	0
2025-05-16	7	2.95	PUT	0	2	456.33	TRUE	0	0
2025-05-16	8	0	PUT	0	0	409.1	TRUE	0	0
2025-05-16	9	0	PUT	0	0	879.81	TRUE	0	0
2025-05-16	10	0	PUT	0	0	503.59	TRUE	0	0
2025-06-20	1	1.85	CALL	0	27	944.55	TRUE	0	0
2025-06-20	2	1.57	CALL	0	171	112.96	TRUE	0	0
2025-06-20	3	1.14	CALL	29	325	100.02	TRUE	-0.34	-0.23
2025-06-20	4	0.5	CALL	102	693	88.53	TRUE	-0.24	-0.32
2025-06-20	5	0.22	CALL	129	630	96.73	FALSE	-0.23	-0.51
2025-06-20	6	0.1	CALL	4	245	102.39	FALSE	-0.08	-0.44
2025-06-20	7	0.07	CALL	2	244	116.54	FALSE	-0.03	-0.3
2025-06-20	8	0.25	CALL	0	26	164.73	FALSE	0	0
2025-06-20	9	0.26	CALL	0	115	182.72	FALSE	0	0
2025-06-20	10	0.05	CALL	2	561	156.12	FALSE	-0.04	-0.44
2025-06-20	11	0.03	CALL	1	750	154.1	FALSE	0.03	0
2025-06-20	12	0.24	CALL	0	5	214.65	FALSE	0	0
2025-06-20	13	0.23	CALL	0	20	225.3	FALSE	0	0
2025-06-20	14	2.7	CALL	0	0	234.96	FALSE	0	0
2025-06-20	15	0.15	CALL	0	3	243.81	FALSE	0	0
2025-06-20	16	2.23	CALL	0	12	251.97	FALSE	0	0
2025-06-20	17	0.1	CALL	0	34	259.53	FALSE	0	0
2025-06-20	18	0.05	CALL	0	560	266.56	FALSE	0	0
2025-06-20	1	0.01	PUT	0	105	246.33	FALSE	0	0
2025-06-20	2	0.22	PUT	0	160	132.01	FALSE	0	0
2025-06-20	3	0.1	PUT	55	415	97.82	FALSE	-0.02	-0.17
2025-06-20	4	0.46	PUT	57	282	94.78	FALSE	0.06	0.15
2025-06-20	5	0.96	PUT	0	165	92.27	TRUE	0	0
2025-06-20	6	3.45	PUT	0	2	93.87	TRUE	0	0
2025-06-20	7	2.95	PUT	0	20	151.33	TRUE	0	0
2025-06-20	8	4.1	PUT	10	7	173.96	TRUE	4.1	0
2025-06-20	9	5.1	PUT	1	11	193.06	TRUE	5.1	0
2025-06-20	10	4.6	PUT	0	0	136.04	TRUE	0	0
2025-06-20	11	5.1	PUT	0	1	252.73	TRUE	0	0
2025-06-20	12	0	PUT	0	0	159.45	TRUE	0	0
2025-06-20	13	0	PUT	0	0	169.69	TRUE	0	0
2025-06-20	14	10.85	PUT	0	0	179.15	TRUE	0	0
2025-06-20	15	12	PUT	0	6	269.67	TRUE	0	0
2025-06-20	16	0	PUT	0	0	196.21	TRUE	0	0
2025-06-20	17	0	PUT	0	0	203.96	TRUE	0	0
2025-06-20	18	0	PUT	0	0	211.28	TRUE	0	0
2025-07-18	1	0	CALL	0	0	439.29	TRUE	0	0
2025-07-18	2	1.8	CALL	0	1	104.35	TRUE	0	0
2025-07-18	3	1.1	CALL	0	80	104.18	TRUE	0	0
2025-07-18	4	0.9	CALL	0	115	96.3	TRUE	0	0
2025-07-18	5	0.35	CALL	33	190	93.48	FALSE	-0.25	-0.42
2025-07-18	6	0.2	CALL	31	149	98.15	FALSE	-0.15	-0.43
2025-07-18	7	0.21	CALL	0	289	108.87	FALSE	0	0
2025-07-18	8	0.1	CALL	3	72	112.57	FALSE	0.1	0
2025-07-18	9	0.06	CALL	77	3225	112.35	FALSE	-0.04	-0.4
2025-07-18	10	0.15	CALL	0	99	128.71	FALSE	0	0
2025-07-18	11	3.15	CALL	0	12	154.39	FALSE	0	0
2025-07-18	12	2.5	CALL	0	1	163.43	FALSE	0	0
2025-07-18	13	0	CALL	0	0	171.55	FALSE	0	0
2025-07-18	14	0	CALL	0	0	178.94	FALSE	0	0
2025-07-18	15	0.8	CALL	0	0	185.69	FALSE	0	0
2025-07-18	16	0	CALL	0	0	191.92	FALSE	0	0
2025-07-18	17	0.54	CALL	0	10	197.69	FALSE	0	0
2025-07-18	18	0.57	CALL	0	12	203.06	FALSE	0	0
2025-07-18	1	0.05	PUT	1	255	218	FALSE	0	0
2025-07-18	2	0.28	PUT	0	11	117.99	FALSE	0	0
2025-07-18	3	0.21	PUT	4	50	101.59	FALSE	0.01	0.05
2025-07-18	4	0.7	PUT	0	1031	93.99	FALSE	0	0
2025-07-18	5	1.2	PUT	0	573	91.77	TRUE	0	0
2025-07-18	6	2.15	PUT	1	91	105.67	TRUE	2.15	0
2025-07-18	7	2.95	PUT	0	4	101.12	TRUE	0	0
2025-07-18	8	4.8	PUT	0	272	110.41	TRUE	0	0
2025-07-18	9	0	PUT	0	0	139	TRUE	0	0
2025-07-18	10	6	PUT	0	20	151.67	TRUE	0	0
2025-07-18	11	0	PUT	0	0	215.52	TRUE	0	0
2025-07-18	12	0	PUT	0	0	157.04	TRUE	0	0
2025-07-18	13	0	PUT	0	0	277.87	TRUE	0	0
2025-07-18	14	9.4	PUT	0	0	203.88	TRUE	0	0
2025-07-18	15	0	PUT	0	0	181.72	TRUE	0	0
2025-07-18	16	0	PUT	0	0	159.64	TRUE	0	0
2025-07-18	17	0	PUT	0	0	226	TRUE	0	0
2025-07-18	18	0	PUT	0	0	201.53	TRUE	0	0
2025-10-17	1	2.5	CALL	0	15	324.89	TRUE	0	0
2025-10-17	2	2.25	CALL	0	13	108.89	TRUE	0	0
2025-10-17	3	1.95	CALL	0	133	102.28	TRUE	0	0
2025-10-17	4	1.1	CALL	10	158	100.54	TRUE	-0.18	-0.14
2025-10-17	5	0.8	CALL	12	319	102.3	FALSE	-0.25	-0.24
2025-10-17	6	0.5	CALL	3	239	94.57	FALSE	-0.2	-0.29
2025-10-17	7	0.5	CALL	0	34	94.29	FALSE	0	0
2025-10-17	8	0.32	CALL	2	48	102.74	FALSE	-0.03	-0.09
2025-10-17	9	0.23	CALL	500	569	101.27	FALSE	0.23	0
2025-10-17	1	0	PUT	0	0	182.84	FALSE	0	0
2025-10-17	2	0.2	PUT	30	40	118.44	FALSE	0.2	0
2025-10-17	3	0.45	PUT	20	17	100.04	FALSE	0	0
2025-10-17	4	1	PUT	4	2	102.78	FALSE	0.1	0.11
2025-10-17	5	1.55	PUT	1	29	91.38	TRUE	-0.15	-0.09
2025-10-17	6	3.1	PUT	0	5	98.78	TRUE	0	0
2025-10-17	7	0	PUT	0	0	99.62	TRUE	0	0
2025-10-17	8	3.88	PUT	1	3	94.4	TRUE	3.88	0
2025-10-17	9	0	PUT	0	0	97.49	TRUE	0	0

Latest CRVS Trades:

Date	Shares	Price
Jun 13, 2022 7:13 PM EST	45	$0.9764
Jun 13, 2022 7:19 PM EST	2	$0.9763
Jun 13, 2022 7:20 PM EST	45	$0.9734
Jun 13, 2022 7:20 PM EST	90	$0.9733
Jun 13, 2022 7:20 PM EST	100	$0.9702

Corvus Pharmaceuticals, Inc (CRVS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Form Type:

Date	Form Type	Form Name	Link
2020-06-15	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000110465920073458/0001104659-20-073458-index.htm
2018-08-01	UPLOAD	SEC-generated letter	https://www.sec.gov/Archives/edgar/data/1626971/000000000018023785/0000000000-18-023785-index.htm
2018-08-24	UPLOAD	SEC-generated letter	https://www.sec.gov/Archives/edgar/data/1626971/000000000018026391/0000000000-18-026391-index.htm
2020-03-12	UPLOAD	SEC-generated letter	https://www.sec.gov/Archives/edgar/data/1626971/000000000020002243/0000000000-20-002243-index.htm
2019-02-14	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1626971/000008025519002716/0000080255-19-002716-index.htm
2020-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1626971/000008025520001312/0000080255-20-001312-index.htm
2019-02-13	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1626971/000031506619000997/0000315066-19-000997-index.htm
2018-06-25	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924318017912/0000899243-18-017912-index.htm
2018-06-25	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924318017913/0000899243-18-017913-index.htm
2018-06-25	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924318017914/0000899243-18-017914-index.htm
2018-06-25	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924318017915/0000899243-18-017915-index.htm
2018-06-25	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924318017916/0000899243-18-017916-index.htm
2018-12-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924318030242/0000899243-18-030242-index.htm
2018-12-10	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924318030539/0000899243-18-030539-index.htm
2018-12-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924318031054/0000899243-18-031054-index.htm
2018-12-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924318031055/0000899243-18-031055-index.htm
2018-12-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924318031057/0000899243-18-031057-index.htm
2018-12-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924318031058/0000899243-18-031058-index.htm
2018-12-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924318031059/0000899243-18-031059-index.htm
2018-12-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924318031061/0000899243-18-031061-index.htm
2018-12-26	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924318031696/0000899243-18-031696-index.htm
2018-12-27	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924318031810/0000899243-18-031810-index.htm
2018-12-31	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924318031989/0000899243-18-031989-index.htm
2019-01-30	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924319002186/0000899243-19-002186-index.htm
2019-01-30	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924319002187/0000899243-19-002187-index.htm
2019-01-30	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924319002190/0000899243-19-002190-index.htm
2019-01-30	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924319002194/0000899243-19-002194-index.htm
2019-06-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924319017182/0000899243-19-017182-index.htm
2019-06-24	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924319017913/0000899243-19-017913-index.htm
2019-06-24	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924319017914/0000899243-19-017914-index.htm
2019-06-24	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924319017917/0000899243-19-017917-index.htm
2019-06-24	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924319017918/0000899243-19-017918-index.htm
2019-06-24	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924319017919/0000899243-19-017919-index.htm
2019-06-24	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924319017924/0000899243-19-017924-index.htm
2019-08-08	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000089924319021352/0000899243-19-021352-index.htm
2019-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1626971/000092189519000470/0000921895-19-000470-index.htm
2019-08-07	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1626971/000092189519002114/0000921895-19-002114-index.htm
2020-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1626971/000092189520000529/0000921895-20-000529-index.htm
2020-02-18	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1626971/000092189520000584/0000921895-20-000584-index.htm
2019-07-01	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000094787119000486/0000947871-19-000486-index.htm
2019-07-01	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000094787119000487/0000947871-19-000487-index.htm
2019-07-02	SC 13D/A	General statement of acquisition of beneficial ownership	https://www.sec.gov/Archives/edgar/data/1626971/000094787119000489/0000947871-19-000489-index.htm
2019-08-08	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000094787119000571/0000947871-19-000571-index.htm
2019-08-08	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000094787119000572/0000947871-19-000572-index.htm
2020-04-17	SC 13D/A	General statement of acquisition of beneficial ownership	https://www.sec.gov/Archives/edgar/data/1626971/000094787120000390/0000947871-20-000390-index.htm
2018-04-27	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material	https://www.sec.gov/Archives/edgar/data/1626971/000110465918027395/0001104659-18-027395-index.htm
2018-05-03	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1626971/000110465918030262/0001104659-18-030262-index.htm
2018-08-17	10-K/A	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1626971/000110465918052661/0001104659-18-052661-index.htm
2018-08-17	CORRESP	Correspondence	https://www.sec.gov/Archives/edgar/data/1626971/000110465918052664/0001104659-18-052664-index.htm
2019-05-09	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1626971/000110465919028231/0001104659-19-028231-index.htm
2019-11-12	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000110465919062177/0001104659-19-062177-index.htm
2020-03-09	S-3	Registration statement under Securities Act of 1933	https://www.sec.gov/Archives/edgar/data/1626971/000110465920030827/0001104659-20-030827-index.htm
2020-03-17	CORRESP	Correspondence	https://www.sec.gov/Archives/edgar/data/1626971/000110465920034837/0001104659-20-034837-index.htm
2020-03-20	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1626971/000110465920036930/0001104659-20-036930-index.htm
2020-03-23	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000110465920037295/0001104659-20-037295-index.htm
2020-04-30	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1626971/000110465920054482/0001104659-20-054482-index.htm
2020-06-15	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000110465920073458/0001104659-20-073458-index.htm
2020-10-05	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000110465920112250/0001104659-20-112250-index.htm
2018-06-25	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000114420418035629/0001144204-18-035629-index.htm
2019-06-24	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000114420419032055/0001144204-19-032055-index.htm
2018-05-03	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184318003466/0001171843-18-003466-index.htm
2018-06-22	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184318004798/0001171843-18-004798-index.htm
2018-06-28	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184318004870/0001171843-18-004870-index.htm
2018-08-02	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184318005700/0001171843-18-005700-index.htm
2018-10-03	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184318006835/0001171843-18-006835-index.htm
2018-10-22	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184318007090/0001171843-18-007090-index.htm
2018-11-01	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184318007480/0001171843-18-007480-index.htm
2018-11-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184318007863/0001171843-18-007863-index.htm
2018-12-14	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184318008443/0001171843-18-008443-index.htm
2019-01-08	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184319000179/0001171843-19-000179-index.htm
2019-01-10	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184319000219/0001171843-19-000219-index.htm
2019-01-28	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184319000555/0001171843-19-000555-index.htm
2019-02-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184319000753/0001171843-19-000753-index.htm
2019-03-07	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184319001583/0001171843-19-001583-index.htm
2019-05-09	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184319003207/0001171843-19-003207-index.htm
2019-06-03	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184319003763/0001171843-19-003763-index.htm
2019-06-24	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184319004128/0001171843-19-004128-index.htm
2019-08-01	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184319005090/0001171843-19-005090-index.htm
2019-10-29	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184319006916/0001171843-19-006916-index.htm
2019-11-08	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184319007381/0001171843-19-007381-index.htm
2019-12-09	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184319008006/0001171843-19-008006-index.htm
2019-12-16	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184319008140/0001171843-19-008140-index.htm
2020-02-03	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184320000651/0001171843-20-000651-index.htm
2020-02-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184320000943/0001171843-20-000943-index.htm
2020-03-05	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184320001518/0001171843-20-001518-index.htm
2020-03-20	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184320001878/0001171843-20-001878-index.htm
2020-04-30	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184320003129/0001171843-20-003129-index.htm
2020-05-29	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184320004067/0001171843-20-004067-index.htm
2020-06-10	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184320004286/0001171843-20-004286-index.htm
2020-07-07	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184320004791/0001171843-20-004791-index.htm
2020-07-30	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184320005409/0001171843-20-005409-index.htm
2020-09-10	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184320006380/0001171843-20-006380-index.htm
2020-09-11	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184320006411/0001171843-20-006411-index.htm
2020-09-17	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184320006493/0001171843-20-006493-index.htm
2020-10-29	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1626971/000117184320007397/0001171843-20-007397-index.htm
2019-01-31	SC 13D/A	General statement of acquisition of beneficial ownership	https://www.sec.gov/Archives/edgar/data/1626971/000119312519023789/0001193125-19-023789-index.htm
2019-02-12	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1626971/000119312519035923/0001193125-19-035923-index.htm
2019-07-29	SC 13D/A	General statement of acquisition of beneficial ownership	https://www.sec.gov/Archives/edgar/data/1626971/000119312519205471/0001193125-19-205471-index.htm
2020-02-12	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1626971/000119312520033205/0001193125-20-033205-index.htm
2020-07-09	SC 13D/A	General statement of acquisition of beneficial ownership	https://www.sec.gov/Archives/edgar/data/1626971/000119312520190472/0001193125-20-190472-index.htm
2019-07-25	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000120919119043285/0001209191-19-043285-index.htm
2020-05-06	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000120919120027486/0001209191-20-027486-index.htm
2020-07-09	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000120919120041990/0001209191-20-041990-index.htm
2018-08-02	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1626971/000155837018006236/0001558370-18-006236-index.htm
2018-11-01	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1626971/000155837018008268/0001558370-18-008268-index.htm
2019-03-07	10-K	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1626971/000155837019001660/0001558370-19-001660-index.htm
2019-04-24	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1626971/000155837019003229/0001558370-19-003229-index.htm
2019-04-24	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material	https://www.sec.gov/Archives/edgar/data/1626971/000155837019003232/0001558370-19-003232-index.htm
2019-05-09	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1626971/000155837019004697/0001558370-19-004697-index.htm
2019-08-01	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1626971/000155837019006824/0001558370-19-006824-index.htm
2019-10-29	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1626971/000155837019009354/0001558370-19-009354-index.htm
2020-03-09	10-K	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1626971/000155837020002232/0001558370-20-002232-index.htm
2020-04-15	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1626971/000155837020003917/0001558370-20-003917-index.htm
2020-04-15	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material	https://www.sec.gov/Archives/edgar/data/1626971/000155837020003923/0001558370-20-003923-index.htm
2020-04-30	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1626971/000155837020004797/0001558370-20-004797-index.htm
2020-07-30	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1626971/000155837020008756/0001558370-20-008756-index.htm
2020-10-29	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1626971/000155837020012039/0001558370-20-012039-index.htm
2019-06-10	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761919013152/0001567619-19-013152-index.htm
2019-06-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761919013222/0001567619-19-013222-index.htm
2019-11-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761919021570/0001567619-19-021570-index.htm
2019-12-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761919023137/0001567619-19-023137-index.htm
2019-12-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761919023139/0001567619-19-023139-index.htm
2019-12-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761919023140/0001567619-19-023140-index.htm
2019-12-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761919023143/0001567619-19-023143-index.htm
2019-12-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761919023146/0001567619-19-023146-index.htm
2019-12-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761919023147/0001567619-19-023147-index.htm
2019-12-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761919023148/0001567619-19-023148-index.htm
2020-03-23	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761920006904/0001567619-20-006904-index.htm
2020-03-23	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761920006905/0001567619-20-006905-index.htm
2020-03-23	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761920006907/0001567619-20-006907-index.htm
2020-03-23	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761920006908/0001567619-20-006908-index.htm
2020-03-23	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761920006909/0001567619-20-006909-index.htm
2020-03-23	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761920006910/0001567619-20-006910-index.htm
2020-06-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761920012097/0001567619-20-012097-index.htm
2020-06-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761920012098/0001567619-20-012098-index.htm
2020-06-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761920012099/0001567619-20-012099-index.htm
2020-06-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761920012100/0001567619-20-012100-index.htm
2020-06-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761920012101/0001567619-20-012101-index.htm
2020-06-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761920012102/0001567619-20-012102-index.htm
2020-09-15	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761920016741/0001567619-20-016741-index.htm
2020-09-15	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1626971/000156761920016744/0001567619-20-016744-index.htm
2020-03-19	EFFECT	Notice of Effectiveness	https://www.sec.gov/Archives/edgar/data/1626971/999999999520000598/9999999995-20-000598-index.htm

Corvus Pharmaceuticals, Inc (CRVS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Corvus Pharmaceuticals, Inc (CRVS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 498%
Institutional Ownership: 6375%

Transaction Date	Insider Name	Insider Title	Type	Shares Number	Shares Price	Total Transaction	Shares Held After Transaction	Link
2018-12-20	RICHARD A MD MILLER	President and CEO	Buy	5,000.00	4.40	22,000.00	1,103,795.00	https://www.sec.gov/Archives/edgar/data/1626971/000089924318031696/0000899243-18-031696-index.htm
2018-12-20	RICHARD A MD MILLER	President and CEO	Buy	5,000.00	4.39	21,950.00	1,108,795.00	https://www.sec.gov/Archives/edgar/data/1626971/000089924318031696/0000899243-18-031696-index.htm
2018-12-04	RICHARD A MD MILLER	President and CEO	Buy	1,502.00	5.95	8,936.90	1,113,795.00	https://www.sec.gov/Archives/edgar/data/1626971/000089924318030242/0000899243-18-030242-index.htm
2018-12-06	RICHARD A MD MILLER	President and CEO	Buy	5,000.00	5.99	29,934.00	1,118,795.00	https://www.sec.gov/Archives/edgar/data/1626971/000089924318030539/0000899243-18-030539-index.htm
2018-12-27	RICHARD A MD MILLER	President and CEO	Buy	20,000.00	3.29	65,884.00	1,128,795.00	https://www.sec.gov/Archives/edgar/data/1626971/000089924318031989/0000899243-18-031989-index.htm
2019-06-07	RICHARD A MD MILLER	President and CEO	Buy	9,212.00	3.37	31,018.65	1,138,007.00	https://www.sec.gov/Archives/edgar/data/1626971/000156761919013222/0001567619-19-013222-index.htm
2019-06-11	RICHARD A MD MILLER	President and CEO	Buy	6,000.00	3.67	22,020.00	1,144,007.00	https://www.sec.gov/Archives/edgar/data/1626971/000156761919013222/0001567619-19-013222-index.htm
2019-06-13	RICHARD A MD MILLER	President and CEO	Buy	343.00	3.52	1,207.36	1,144,350.00	https://www.sec.gov/Archives/edgar/data/1626971/000089924319017182/0000899243-19-017182-index.htm
2019-06-14	RICHARD A MD MILLER	President and CEO	Buy	11,657.00	3.40	39,666.44	1,156,007.00	https://www.sec.gov/Archives/edgar/data/1626971/000089924319017182/0000899243-19-017182-index.htm
2019-08-06	RICHARD A MD MILLER	President and CEO	Buy	5,000.00	3.58	17,875.00	1,161,007.00	https://www.sec.gov/Archives/edgar/data/1626971/000089924319021352/0000899243-19-021352-index.htm
2019-08-07	RICHARD A MD MILLER	President and CEO	Buy	2,500.00	3.54	8,850.00	1,163,507.00	https://www.sec.gov/Archives/edgar/data/1626971/000089924319021352/0000899243-19-021352-index.htm
2019-11-12	RICHARD A MD MILLER	President and CEO	Buy	272.00	2.90	788.80	1,163,779.00	https://www.sec.gov/Archives/edgar/data/1626971/000156761919021570/0001567619-19-021570-index.htm
2019-11-13	RICHARD A MD MILLER	President and CEO	Buy	14,736.00	3.00	44,240.42	1,178,515.00	https://www.sec.gov/Archives/edgar/data/1626971/000156761919021570/0001567619-19-021570-index.htm
2020-07-08	Holdings A/S Novo	10% Share Holder	Sell	741,440.00	5.37	3,985,165.86	1,389,498.00	https://www.sec.gov/Archives/edgar/data/1626971/000120919120041990/0001209191-20-041990-index.htm
2020-07-07	Holdings A/S Novo	10% Share Holder	Sell	796,622.00	5.25	4,183,380.77	2,130,938.00	https://www.sec.gov/Archives/edgar/data/1626971/000120919120041990/0001209191-20-041990-index.htm
2018-12-21	LEIV LEA	Chief Financial Officer	Buy	24,700.00	4.15	102,408.67	24,700.00	https://www.sec.gov/Archives/edgar/data/1626971/000089924318031810/0000899243-18-031810-index.htm
2019-07-25	Holdings A/S Novo	10% Share Holder	Sell	1,400,000.00	4.00	5,600,000.00	2,927,560.00	https://www.sec.gov/Archives/edgar/data/1626971/000120919119043285/0001209191-19-043285-index.htm
2019-06-06	LEIV LEA	Chief Financial Officer	Buy	15,500.00	3.56	55,180.00	40,200.00	https://www.sec.gov/Archives/edgar/data/1626971/000156761919013152/0001567619-19-013152-index.htm
2019-07-24	Holdings A/S Novo	10% Share Holder	Sell	53,240.00	5.01	266,711.10	4,327,560.00	https://www.sec.gov/Archives/edgar/data/1626971/000120919119043285/0001209191-19-043285-index.htm
2019-07-23	Holdings A/S Novo	10% Share Holder	Sell	39,716.00	5.32	211,134.23	4,380,800.00	https://www.sec.gov/Archives/edgar/data/1626971/000120919119043285/0001209191-19-043285-index.htm
2019-06-07	LEIV LEA	Chief Financial Officer	Buy	10,000.00	3.38	33,800.00	50,200.00	https://www.sec.gov/Archives/edgar/data/1626971/000156761919013152/0001567619-19-013152-index.htm
2019-06-27	ORBIMED ADVISORS LLC	Director	Buy	32,923.00	3.34	109,962.82	6,000,507.00	https://www.sec.gov/Archives/edgar/data/1626971/000094787119000486/0000947871-19-000486-index.htm
2019-06-27	Peter A. Thompson	Director	Buy	32,923.00	3.34	109,962.82	6,000,507.00	https://www.sec.gov/Archives/edgar/data/1626971/000094787119000487/0000947871-19-000487-index.htm
2019-06-28	ORBIMED ADVISORS LLC	Director	Buy	565,178.00	3.72	2,102,462.16	6,565,685.00	https://www.sec.gov/Archives/edgar/data/1626971/000094787119000486/0000947871-19-000486-index.htm
2019-06-28	Peter A. Thompson	Director	Buy	565,178.00	3.72	2,102,462.16	6,565,685.00	https://www.sec.gov/Archives/edgar/data/1626971/000094787119000487/0000947871-19-000487-index.htm
2019-07-01	ORBIMED ADVISORS LLC	Director	Buy	59,243.00	3.91	231,640.13	6,624,928.00	https://www.sec.gov/Archives/edgar/data/1626971/000094787119000486/0000947871-19-000486-index.htm
2019-07-01	Peter A. Thompson	Director	Buy	59,243.00	3.91	231,640.13	6,624,928.00	https://www.sec.gov/Archives/edgar/data/1626971/000094787119000487/0000947871-19-000487-index.htm
2019-08-06	ORBIMED ADVISORS LLC	Director	Buy	142,656.00	3.51	500,722.56	6,767,584.00	https://www.sec.gov/Archives/edgar/data/1626971/000094787119000571/0000947871-19-000571-index.htm
2019-08-06	Peter A. Thompson	Director	Buy	142,656.00	3.51	500,722.56	6,767,584.00	https://www.sec.gov/Archives/edgar/data/1626971/000094787119000572/0000947871-19-000572-index.htm

Corvus Pharmaceuticals, Inc

(NASDAQ:CRVS)